5-HT1A receptor antagonists(Serotonin 1a (5-HT1a) receptor antagonists), 5-HT2A receptor agonists(Serotonin 2a (5-HT2a) receptor agonists), 5-HT2C receptor agonists(Serotonin 2c (5-HT2c) receptor agonists)

Therapeutic Areas

Nervous System DiseasesNeoplasmsImmune System Diseases+ [5]

Active Indication

Depressive Disorder, Treatment-ResistantDepressive Disorder, MajorStress Disorders, Post-Traumatic+ [41]

Inactive Indication

Abnormalities, Drug-InducedAmnesiaBinge-Eating Disorder+ [10]

Originator Organization-

Active Organization

Filament Health Corp.

Atai Beckley NV

Avextra Pharma GmbH

+ [35]

Inactive Organization

Revive Therapeutics Ltd.

Ceruvia Lifesciences LLC.

Beckley Psytech Ltd.

+ [2]

License Organization

Revive Therapeutics Ltd.

Psyence Biomedical Ltd.

Psirenity

+ [17]

Drug Highest PhaseApproved

First Approval Date

Australia (01 Sep 2025),

Depressive Disorder, Treatment-Resistant

RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Innovative Licensing and Access Pathway (United Kingdom), Commissioner's National Priority Voucher (United States)

Structure/Sequence

Molecular FormulaC12H17N2O4P

InChIKeyQVDSEJDULKLHCG-UHFFFAOYSA-N

CAS Registry520-52-5

325

Clinical Trials associated with Psilocybin

NCT06102434

/ SuspendedEarly Phase 1IIT

Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use Disorder

The purpose of this study is to establish the safe administration of psilocybin in individuals with cocaine use disorder in terms of cardiovascular (e.g., heart rate) and subjective (e.g., mood) effects. The study's subject population consists of men and women between the ages of 21 and 55 from the Los Angeles area that meet criteria for cocaine use disorder and express an interest in ceasing cocaine use. 25 mg oral psilocybin will be administered to 10 individuals (separately) during a single laboratory visit. The laboratory visit will take place from 9 am until 3 pm within a comfortable, living room like environment. Within this study session room, participants will be accompanied by two clinicians. Participants will then consume the psilocybin capsule, and thereafter will be encouraged to lie down on a couch and introspect on the experience. At one-hour intervals following ingestion, participants will be tested briefly for changes in heart rate, blood pressure, and subjective effects. No blood draws, behavioral assessments, or neuroimaging is included in the study. Following the laboratory visit, investigators will check-in on participants remotely, after 48 hours, and 10, 50, and 90 days from the psilocybin session.

Start Date01 Feb 2029

Sponsor / Collaborator

University of California, Los Angeles

NCT06005662

/ WithdrawnPhase 2IIT

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial

This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care buprenorphine treatment for Opioid use disorder (OUD). Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with buprenorphine maintenance, quality of life, and mood.

Start Date01 Apr 2027

Sponsor / Collaborator

The Johns Hopkins University

NCT07566104

/ Not yet recruitingPhase 2IIT

Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive Disorder

This study will seek to determine the (1) acceptability and (2) feasibility of psilocybin as an adjunct to cognitive-behavioral therapy, delivered as a group treatment (G-PACBT) for major depressive disorder and (3) explore the clinical effects of G-PACBT on depressive symptoms and psychosocial functioning.

Start Date01 Jan 2027

Sponsor / Collaborator

University of California, Los Angeles

100 Clinical Results associated with Psilocybin

100 Translational Medicine associated with Psilocybin

100 Patents (Medical) associated with Psilocybin

2,659

Literatures (Medical) associated with Psilocybin

01 Nov 2026·JOURNAL OF AFFECTIVE DISORDERS

Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression

Article

Author: Kelly, Carlton M ; Aaronson, Scott ; Bostian, Catherine M ; Ellis, Sara ; Fradet, Mathieu ; Suppes, Trisha ; Donnelly, Anna ; Ostacher, Michael

BACKGROUND:

Psilocybin has demonstrated promise for improving depressive symptoms in treatment-resistant depression, but its effects on anxiety, quality of life, functioning, and posttraumatic stress symptoms are less well studied. This study reports exploratory findings from an open-label trial in Veterans with TRD.

METHODS:

Participants received a single 25-mg dose of psilocybin administered with psychological support. The primary endpoint was assessed 3 weeks post-dose, with follow-up extending to 12 months. Outcomes included anxiety severity (GAD-7), quality of life (Q-LES-Q-SF), functional impairment (WSAS), and posttraumatic stress disorder symptoms (PCL-5). Experiential outcomes were measured with the Mystical Experience Questionnaire (MEQ), Challenging Experiences Questionnaire (CEQ-30), and Emotional Breakthrough Inventory (EBI). Mixed-effects models were used to evaluate longitudinal changes, and correlation analyses examined associations between measures and changes in depressive symptoms on the Montgomery-Åsberg Depression Rating Scale.

RESULTS:

Fifteen participants were included, with ten completing long-term follow-up. GAD-7 scores demonstrated sustained improvements through 12 months, with a 59% reduction from baseline at Week 3. Q-LES-Q-SF gains were significant through Week 12, with a 24% increase at Week 3, and WSAS improvements persisted through Month 6 before declining, with a 46% reduction at Week 3. These effects were no longer statistically significant after accounting for improvements in depression. Unadjusted PCL-5 reductions were observed at all timepoints. Exploratory analyses of acute subjective experiences did not correlate to treatment response.

LIMITATIONS:

This study is limited by its small sample size and open-label design.

CONCLUSIONS:

Psilocybin with psychological support was associated with improvements in anxiety, quality of life, functioning, and PTSD symptoms which largely correlated to concurrent improvements in depressive symptoms.

CLINICAL TRIAL:

NCT04433858.

01 Oct 2026·JOURNAL OF PSYCHIATRIC RESEARCH

Psychedelics and autism spectrum disorder: Mechanistic insights, translational evidence and ethical challenges

Review

Author: Lodetti, Guilherme ; Gonçalves, Cinara Ludvig ; Rico, Eduardo Pacheco ; Bolan, Sofia Januário ; Claudino Dos Santos, Júlio César ; Viana, Germano Lapa

Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition characterized by persistent deficits in social communication and interaction, restricted and repetitive patterns of behavior, and sensory processing alterations, frequently accompanied by anxiety, emotional dysregulation, and other psychiatric comorbidities. Despite advances in behavioral and pharmacological interventions, effective treatments for core ASD symptoms remain limited. Psychedelic compounds have recently emerged as potential therapeutic agents in psychiatry because of their ability to modulate serotonergic and glutamatergic signaling, enhance neuroplasticity, reorganize large-scale brain networks, and influence neurobiological pathways implicated in ASD. In this narrative review, we examine the mechanistic rationale supporting psychedelic-based approaches in ASD, including 5-HT2A receptor activation, oxytocin-serotonin interactions, excitation-inhibition dynamics, functional connectivity, and glutamatergic modulation associated with ketamine and related compounds. We also summarize current clinical and preclinical evidence involving substances such as psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and ketamine. Particular attention is given to the distinction between core ASD symptoms and associated symptom domains. Current evidence does not support the direct treatment of core social communication deficits or restricted and repetitive behaviors; however, psychedelics may hold greater potential for dimensions such as social anxiety, emotional dysregulation, cognitive rigidity, and co-occurring mood symptoms. Ethical, regulatory, and developmental safety considerations are also discussed, particularly regarding neurodivergent populations and the absence of robust pediatric evidence. Although direct clinical studies in ASD remain scarce, psychedelic-assisted interventions represent a promising translational avenue that warrants further rigorous investigation through carefully designed clinical trials.

01 Sep 2026·INTERNATIONAL JOURNAL OF DRUG POLICY

Balancing safety and access in Oregon’s psilocybin services

Article

Author: Yaden, David B ; Cheung, Katherine ; Propes, Caleigh

As jurisdictions across the U.S. consider enacting policies that facilitate access to psychedelics, they must determine how the desire to expand access to these substances should be weighed against the need to adequately protect safety. Oregon's psilocybin services program offers an important early case study of this balance in practice. Under the Psilocybin Services Act, adults over 21 are permitted to access psilocybin in Oregon at licensed service centers under facilitator supervision, with no referral from a medical practitioner, or clinical supervision, needed. Drawing on the first full year of data published by the Oregon Health Authority, this commentary examines how safety and access are being balanced through Oregon's policy. Reported adverse reactions in 2025 were relatively uncommon: however, Oregon's reporting framework sets a high threshold for reportable events. Access also remains limited, with most clients being of high-income and from outside Oregon. At the same time, the program has expanded supervised psilocybin use beyond strictly medical uses, with a proportion of clients reporting using psilocybin services for general health and wellness. Others report using psilocybin services for more medical-type motivations, such as for depression and anxiety. Overall, we argue that Oregon's broad eligibility criteria and supervision requirements may raise several safety concerns, particularly when clients with clinical symptoms seek services.

1,271

News (Medical) associated with Psilocybin

19 hours ago

·www.einpresswire.com

Scottsdale Research Institute Announces Submission of Investigational New Drug (IND) Application to FDA for Ibogaine HCl

We appreciate FDA's acceptance of our IND application for review and assignment of IND 183727. This is a step toward rigorously evaluating ibogaine hydrochloride under the FDA's regulatory framework.” — Dr. Sue Sisley PHOENIX, AZ, UNITED STATES, July 29, 2026 / EINPresswire.com / -- Ibogaine HCl is an investigational neuroplastogen designed to promote neuroplasticity and restore neural function disrupted by psychological trauma, traumatic brain injury, and substance use disorders. The active pharmaceutical ingredient (API) will be supplied by Psygen (Canada) utilizing Scottsdale Research Institute’s DEA Schedule I Importer Registration. PTSD, TBI, and opioid use disorder affect millions of Americans—including military veterans and first responders—for whom existing treatment options remain inadequate. If authorized by the FDA and Institutional Review Board (IRB), the planned Phase 1 clinical trial is expected to begin in early 2027 and will support advancement into Phase 2 clinical development. Scottsdale Research Institute/Field to Healed Foundation (SRI/F2H), a nonprofit clinical research organization dedicated to advancing innovative therapies for military veterans, first responders, and others living with post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and substance use disorders, today announced the submission of its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Ibogaine Hydrochloride (Ibogaine HCl) , an investigational neuroplastogen being developed for the treatment of PTSD, TBI, and opioid use disorder (OUD). Acceptance of the IND application for review represents an important regulatory milestone in the clinical development of ibogaine as an FDA-regulated investigational medicine. Subject to FDA and IRB authorization, Scottsdale Research Institute anticipates initiating its Phase 1 clinical trial in early 2027 to evaluate the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamic effects of Ibogaine HCl in military veterans and civilians living with PTSD and TBI. “We appreciate the FDA’s acceptance of our IND application for review and the assignment of IND 183727,” said Dr. Sue Sisley, MD, President and Principal Investigator of Scottsdale Research Institute. “This submission represents an important step toward rigorously evaluating ibogaine hydrochloride under the FDA’s regulatory framework. Millions of individuals living with PTSD, traumatic brain injury, opioid use disorder, and related conditions continue to face significant unmet medical needs. We are proud of the scientific and clinical team that made this milestone possible and look forward to working collaboratively with the FDA as we advance this important research program.” Ibogaine HCl represents a novel therapeutic approach that combines neuroplasticity with a unique polypharmacologic mechanism of action. By interacting with multiple neurotransmitter systems, ibogaine has demonstrated the potential in preclinical and early clinical studies to induce neuroplastic changes that may help restore neural circuits affected by psychological trauma, traumatic brain injury, and chronic substance use. Unlike currently available therapies that primarily target individual symptoms, Ibogaine HCl is being investigated for its potential to address underlying neurological dysfunction that contributes to PTSD, TBI, opioid use disorder, depression, anxiety, and cognitive impairment. Scottsdale Research Institute’s Phase 1 clinical trial is designed to generate critical safety, pharmacokinetic, cardiac safety, and dose-ranging data that will inform future Phase 2 studies evaluating the efficacy of Ibogaine HCl. SRI is collaborating with Brian Anderson, M.D., Associate Professor at the University of California, San Francisco (UCSF), to advance the clinical development program. In addition, SRI is building collaborative relationships with Native American Tribes and tribal partners to support culturally informed and ethically responsible psychedelic research. These relationships form the foundation of an emerging Psychedelic Research Tribal Consortium, led by Michelle Driver, which will help integrate indigenous knowledge and ethical stewardship into the program’s research and development. About Scottsdale Research Institute Scottsdale Research Institute (SRI) is a nonprofit clinical research organization dedicated to developing innovative therapies for PTSD, traumatic brain injury, chronic pain, and substance use disorders through FDA-regulated clinical trials. Working in collaboration with leading academic medical centers, tribal partners, and scientific experts, SRI is committed to generating high-quality clinical evidence that expands treatment options for military veterans, first responders, and patients with serious unmet medical needs. SRI is also advancing HRTT21, an FDA-authorized Investigational New Drug consisting of whole natural psilocybin mushrooms. The Phase 1 clinical trial is expected to conclude in August 2026, with submission of the Phase 2 IND application anticipated shortly thereafter. Upon authorization, HRTT21 is expected to qualify as an Eligible Investigational Drug (EID) under applicable federal Right to Try provisions. ### Dr. Sue Sisley Scottsdale Research Institute +1 480-326-6023 SueSisleyMD@srilaboratory.com Visit us on social media: LinkedIn Instagram Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Phase 1IND

19 hours ago

·www.globenewswire.com

Rose Hill Life Sciences Appoints Bryan Smith as Scientific Advisor

Veteran Drug Discovery Executive Brings Nearly Two Decades of Oncology and Translational Research Leadership to Advance Rose Hill’s Clinical PipelineBOSTON, July 29, 2026 (GLOBE NEWSWIRE) -- Rose Hill Life Sciences (“Rose Hill” or “the Company”), a clinical-stage biotechnology company advancing psychedelic therapeutics for neurological and psychiatric conditions, announced the appointment of Bryan Smith as Scientific Advisor. Smith brings nearly two decades of drug discovery and biological sciences leadership to Rose Hill, where he will inform the scientific strategy across the company’s preclinical and clinical programs and guide its proprietary pipeline from preclinical development through clinical validation. Smith joins Rose Hill following a nearly 20-year tenure at Deciphera Pharmaceuticals, where he rose to Vice President of Biological Sciences and Research Site Head. At Deciphera, he played a central role in advancing novel small molecule oncology therapeutics from early concept through clinical development and regulatory approvals, gaining deep expertise in target identification, drug discovery strategy, translational research, biomarker development, and IND/NDA preparation. He most recently served as a Senior Advisor at Deciphera and now serves on its Scientific Advisory Board. Smith holds a PhD in Biochemistry from the University of Wisconsin–Madison and a BS in Biochemistry from the University of Nebraska–Lincoln. He also operates Smith Biotech Consulting LLC, through which he has provided strategic guidance on drug discovery, preclinical and clinical planning, pipeline prioritization, and regulatory documentation. “Bryan’s breadth of experience—spanning nearly two decades of rigorous drug discovery, translational science, and regulatory preparation—makes him ideally suited to advise Rose Hill in our scientific agenda at this pivotal stage,” said Jama Pitman, Chief Executive Officer of Rose Hill Life Sciences. “As our flagship psilocybin-for-stroke-recovery program advances through Phase 1 in partnership with Johns Hopkins School of Medicine, and as we build out our broader pipeline in depression, PTSD, and autism spectrum disorder, Bryan’s expertise in moving complex therapeutics from concept to clinic to regulatory approval will be critical. We are building this company with the same scientific discipline and rigor that defines the best drug development organizations in the world, and Bryan embodies exactly that standard.” “Rose Hill is tackling some of the most significant unmet needs in medicine, with a scientific foundation and institutional partnerships that I find genuinely compelling,” said Bryan Smith, Scientific Advisor of Rose Hill. “The combination of a first-in-class clinical program in post-stroke motor recovery, a vertically integrated development model, and a team that holds itself to the same evidentiary standards as the best drug development organizations in the world, creates a platform with real potential to reshape how neurological and psychiatric conditions are treated. I look forward to bringing the full weight of my drug discovery and translational research experience to bear as we advance this pipeline responsibly and with the scientific credibility that patients and the broader medical community deserve.” In his role as Scientific Advisor, Smith will help define Rose Hill’s scientific strategy and research operations, direct translational research and biomarker programs, and support the company’s regulatory and IND/NDA documentation processes. Alongside the company’s leadership team, Bryan works closely with Rose Hill’s research partners at Johns Hopkins University, the University of Guelph, and other research partners. About Rose Hill Life Sciences:Rose Hill Life Sciences is a clinical-stage biotechnology company advancing psilocybin-based therapeutics for neurological and psychiatric conditions. The Company maintains active research collaborations across four clinical programs targeting stroke recovery, depression, autism spectrum disorder, and PTSD. Rose Hill's vertically integrated operations — spanning cultivation and extraction in Jamaica, formulation and manufacturing, and clinical development partnerships across the United States and Canada — support pharmaceutical-grade quality, supply chain control, and scientific rigor from source to patient. As the world's inaugural legal exporter of psilocybin, Rose Hill is committed to advancing evidence-based treatments and setting new standards for safety, efficacy, and responsible development in psychedelic medicine. For more information, visit rosehill.life. Rose Hill Life Sciences is wholly owned by Rose Hill Health Holdings LLC. Media Contactrosehill@kcsa.com

Executive Change

29 Jul 2026

·www.biospace.com

Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026

Compass Management will host a conference call at 8:00 am ET (1:00 pm UK) LONDON & NEW YORK--(BUSINESS WIRE)-- $CMPS #Biotech --Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the second quarter and first half ended June 30, 2026, on August 5, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on August 5, 2026. A live webcast of the call will be available on the Compass Pathways website at: . The webcast will be archived for 30 days. About Compass Pathways ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 is a potentially first-in-class treatment and has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. We are leading the world’s largest classic psychedelic clinical program in TRD, and building upon that robust foundation, we are executing a late-stage trial evaluating COMP360 for PTSD, another condition with high unmet need. Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability with infrequent dosing. Compass is headquartered in London, UK, with a U.S. office in New Jersey. We are driven by our purpose of unlocking pathways to be – opening futures filled with possibility. Together, we are on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery, because every journey needs a Compass. Contacts Enquiries Media: Dana Sultan-Rothman, media@compasspathways.com Investors: Stephen Schultz, stephen.schultz@compasspathways.com , +1 401 290 7324

Financial StatementBreakthrough Therapy

100 Deals associated with Psilocybin

External Link

KEGG	Wiki	ATC	Drug Bank
-	Psilocybin	-	DB11664

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Depressive Disorder, Treatment-Resistant	Australia	Optimi Health Corp.	01 Sep 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Stress Disorders, Post-Traumatic	Phase 3	-	Compass Pathways Plc	01 Sep 2026
Depressive Disorder, Major	Phase 3	United States	Usona Institute	13 Mar 2024
Peripheral Nervous System Diseases	Phase 2	United States	The University of Texas MD Anderson Cancer Center	04 Nov 2026
Parkinson Disease	Phase 2	United States	Yale University	01 Jul 2026
Low Back Pain	Phase 2	United States	Yale University	01 Jun 2026
Gambling	Phase 2	France	Nantes University Hospital	01 Apr 2026
Stuttering	Phase 2	United States	NYU Langone Health	15 Jan 2026
Breast Cancer	Phase 2	Australia	Psyence Australia Pty Ltd.	01 Oct 2025
Endometrial Carcinoma	Phase 2	Australia	Psyence Australia Pty Ltd.	01 Oct 2025
Kidney Neoplasms	Phase 2	Australia	Psyence Australia Pty Ltd.	01 Oct 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05523401 (Pubmed \| Neuropsychopharmacology)	Phase 1	-	24	2C-B 10mg	ojweuvhann(omosoxsvhg) = Only psilocybin induced 'bad drug effects' and 'anxiety' compared with placebo vbxqaspiqa (spgqqwsjba ) View more	Positive	01 Jul 2026
NCT05523401 (Pubmed \| Neuropsychopharmacology)	Phase 1	-	24	MDMA 125mg		Positive	01 Jul 2026
NCT03289949 (NeuroPharm2, Pubmed \| J Psychopharmacol)	Phase 1	Cluster Headache	11	Psilocybin (Chronic Cluster Headache)	zmrmgehdze(fpnnbfecor) = abxwmyffvc ywkrknpmyv (rduehmmdhz )	Positive	29 May 2026
NCT06835699 (Open Label Psilocybin Brain Stimulation and Imaging Pilot Study, Pubmed \| Psychopharmacology (Berl))	Phase 1	Syncope, Vasovagal	1	Psilocybin 25 mg	ogwamrmylo(kwzvgzupzs) = eizfcksscu hbketwshau (crvfgxlvcc )	Positive	28 May 2026
NCT05227612 (CTgov)	Phase 1	Depressive Disorder, Major	16	psilocybin	nqcenmhtnt(xbteicpzdm) = zqwuarnkic qljcuqblvx (hqhepgijfp, 2.2) View more	-	19 May 2026
NCT02037126 (CTgov)	Phase 2	Cocaine-Related Disorders	40	Psilocybin (Psilocybin Administration)	kspxuiacpq(uuxaqozvma) = tanofoulyz arhsqrjpty (bqskzxygoc, 1.01) View more	-	18 May 2026
NCT02037126 (CTgov)	Phase 2	Cocaine-Related Disorders	40	Diphenhydramine (Diphenhydramine Administration)	kspxuiacpq(uuxaqozvma) = dylzrniyym arhsqrjpty (bqskzxygoc, 5.25) View more	-	18 May 2026
NCT03300947 (Pubmed \| J Psychopharmacol)	Phase 1	Obsessive-Compulsive Disorder	15	High-dose psilocybin	dsbumdqpri(piodlpnahq) = sknhknvzlg lcojrwgida (apxrdtyfim ) View more	Positive	01 May 2026
NCT03866174 (CTgov)	Phase 2	Depressive Disorder, Major	347	Set and Setting (SaS) Protocol+Psilocybin (Psilocybin)	zifbzeddjp(wagngyrppd) = qpxootnjnf ibvxumgjzo (tkbsealarq, 1.8) View more	-	22 Apr 2026
NCT03866174 (CTgov)	Phase 2	Depressive Disorder, Major	347	Set+Niacin (Niacin)	zifbzeddjp(wagngyrppd) = hkvvzhlxre ibvxumgjzo (tkbsealarq, 1.9) View more	-	22 Apr 2026
NCT05259943 (Pubmed \| BJPsych Open)	Phase 2	Depressive Disorder, Major	40	Microdosing psilocybin	ekzycabzqk(iiqisqfcnp) = ucyuvjtahg npaljvizje (unjnuvkoad ) View more	Positive	01 Mar 2026
NCT04950608 (PATH, CTgov)	Phase 2	Advanced cancer	15	Psilocybin	liwxphfmzc = ysdbwukhbw smbgzyvrcm (naqtnibxma, qwvutrxczi - uwbxxmyzjv) View more	-	02 Sep 2025
NCT04424225 (CTgov)	Phase 1	Psychedelic \| Perceptual Disorders \| Visual Suppression	10	Psilocybin (Psilocybin)	czkrvouecb(kstromfyni) = lcghhyexuj xxcuofwyqg (iwlfymtzan, .11731) View more	-	27 Jun 2025
NCT04424225 (CTgov)	Phase 1	Psychedelic \| Perceptual Disorders \| Visual Suppression	10	Niacin (Niacin)	czkrvouecb(kstromfyni) = cxapiojpwj xxcuofwyqg (iwlfymtzan, .04398) View more	-	27 Jun 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis